非核苷类抗乙型肝炎病毒药物的研究进展

Advances in the research on non-nucleos(t)ide chemicals as anti-HBV agents

目前美国FDA批准的抗乙型肝炎病毒(HBV)药物分为两类:免疫调节剂和核苷类似物。但免疫调节剂的副作用和核苷类似物耐药性病毒株的出现使得慢性乙型肝炎的临床治疗仍然面临着巨大的挑战。因而,非核苷类抗HBV药物的研究引起广泛关注。本文按照不同的结构和作用机制对此类药物的研究进展做一综述。

Current FDA approved drugs for hepatitis B virus （HBV） infection are nucleos（t） ide analogs and immune modulators. However, the use of immune modulators has many side effects while that of nucleos（t） ide analogs can lead to the emergence of resistant viruses. Hence, treatment of chronic hepatitis B remains a clinical challenge. So, new classes of chemicals with novel stuctures and actions against HBV replication arouses much attention. This article summarizes recent research progress of these nonnucleos（t） ide anti-HBV chemicals according to their strcutures and actions.